je.st
news
Tag: patients
Fearing Stigma, Some Hospitals Are Reluctant To Treat Ebola Patients
2014-11-29 22:26:45| Biotech - Topix.net
Since the Centers for Disease Control and Prevention started work on building a network of hospitals to provide effective Ebola patient care earlier this year, only a couple dozen American facilities - a tiny fraction of the more than 5,000 hospitals across the country - have volunteered their services. That's because concerns about exorbitant health care costs, unwanted attention, and the fears of other patients loom large among hospital administrators, further complicating the Obama administration's plans to set up one Ebola facility in every state and provide additional support in New York, Chicago, Puerto Rico, and Washington, D.C., as outlined in a $6 billion emergency fund request .
Tags: patients
treat
hospitals
reluctant
Researchers set up innovative project to monitor physical activity of patients with haemophilia
2014-11-26 20:37:20| Semiconductors - Topix.net
The research group Intelligent Data Analysis Laboratory from the School of Engineering Universitat de Valencia and a team of scientists at the Faculty of Physiotherapy led by Professor Felipe Querol have set up an innovative project for monitoring the physical activity of people with haemophilia through individual devices with the purpose of developing patterns which help to improve their quality of life and treatments.
Tags: with
set
project
activity
VYTORIN (ezetimibe/simvastatin) Significantly Reduced Cardiovascular Events More than Simvastatin Alone in Patients Presenting with Acute Coronary Syndromes in the Investigational IMPROVE-IT Study
2014-11-17 17:45:00| Merck.com - Product News
Dateline City: CHICAGO CHICAGO--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the investigational IMPROVE-IT study met its primary and all secondary composite efficacy endpoints. Language: English Contact: MerckMedia Contact:Pam Eisele, 267-305-3558orInvestor Contact:Joe Romanelli, 908-423-5185 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: the
events
study
reduced
Bristol-Myers Drug Shows Promise for Skin-Cancer Patients
2014-11-16 19:05:01| Biotech - Topix.net
A new Bristol-Myers Squibb Co. drug helped skin-cancer patients live longer than those who received chemotherapy in a clinical trial, the latest evidence behind a promising new crop of drugs that work by unleashing the body's immune system against tumors.
Tags: shows
drug
patients
promise
MSD Announces Positive Study Investigating the Use of Pembrolizumab Compared to Chemotherapy in Patients with Ipilimumab-Refractory Advanced Melanoma
2014-11-16 10:25:00| Merck.com - Research & Development News
Dateline City: ZURICH Pembrolizumab Demonstrated Superiority to Chemotherapy for Primary Endpoint of Progression-Free Survival Findings Presented for First Time at Society of Melanoma Research (SMR) 2014 International Congress ZURICH--(BUSINESS WIRE)--MSD, known as Merck in the United States and Canada, announced today that a pre-specified analysis of investigational data from a pivotal Phase 2 study (KEYNOTE-002) showed pembrolizumab, the companys anti-PD-1 therapy, substantially improved the primary endpoint of progression-free survival (PFS, as assessed by RECIST 1.1, independent central review) (HR 0.57 and 0.50 for 2 mg/kg and 10 mg/kg every three week doses, respectively), compared to chemotherapy (P<0.0001 for both comparisons) in patients with ipilimumab- Language: English Contact: MSDMedia:Lainie Keller, +1-908-236-5036Claire Mulhearn, +1-908-236-1118orInvestor:Joseph Romanelli, +1-908-423-5185Justin Holko, +1-908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: with
advanced
study
positive
Sites : [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] next »